Towards the integration of transcranial magnetic stimulation and electroencephalography coupling as an early biomarker of Parkinson’s disease in de novo patients

PhD Student: Brice Passera
Laboratories: GIN / LPNC

Parkinson’s disease (PD) is the second most frequent neurodegenerative disorder. Unfortunately, there is no cure for PD and no neuroprotective treatment. Besides motor impairment, PD patients show an alteration in several cognitive processes. The disease does not progress in the same way in patients and some will rapidly develop dementia. Thus one of the challenges associated with PD is to identify subtypes to predict its evolution and to individualize the treatment accordingly. The aim of our project is to identify biomarkers based on non-motor subtypes allowing for an earlier diagnosis of PD. We assume that in subtypes characterized by prevalent cognitive issues the deficit in cortical excitability in the fronto-parietal networks could be a biomarker in early stage of the pathology. We will study the cortical excitability in de novo PD patients, combining cortical stimulation and electroencephalography recording, using concepts of functional cytoarchitectonics developed by the GIN and LPNC and functional tractography, probing local and large scale neuronal communication.


Published on November 21, 2017